Arava/Methotrexate Combo May Expand Indication To Refractory Patients
A planned combination trial of Hoechst Marion Roussel's Arava and methotrexate in rheumatoid arthritis may justify expanding the use of leflunomide to patients not adequately controlled by methotrexate alone, HMR consultant Marc Hochberg, MD, University of Maryland, told the Arthritis Advisory Committee Aug. 7.
You may also be interested in...
Centocor will have two-year x-ray data on Remicade in the prevention of rheumatoid arthritis progression available for review at the upcoming meeting of FDA's Arthritis Drugs Advisory Committee.
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011